GCM
CGTX icon

Graham Capital Management’s Cognition Therapeutics CGTX Stock Holding History

Graham Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-151,870
Closed -$205K – 1206
2025
Q4 		$205K Sell
151,870
-74,687
-33% -$121K ﹤0.01% 1032
2025
Q3 		$306K Buy
+226,557
New +$309K ﹤0.01% 846

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Graham Capital Management's CGTX Position: Q1 2026 in Review

Graham Capital Management sold out of Cognition Therapeutics (CGTX) in Q1 2026, closing a stake of 151,870 shares — an estimated $205K sold.

Graham Capital Management first reported a position in CGTX in Q3 2025 and held it in 2 quarters. The position peaked at $306K in Q3 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Graham Capital Management reported no remaining Cognition Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 151,870 Cognition Therapeutics shares in Q1 2026, an estimated $205K.
  • Graham Capital Management first reported a position in Cognition Therapeutics in Q3 2025 and held it in 2 quarters.
  • Graham Capital Management's Cognition Therapeutics position peaked at $306K in Q3 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.